(AOF) – Lysogene announces that no takeover offer has been filed before the filing deadline set for April 12, 2023, despite two successive postponements. As a reminder, the search procedure for a buyer was part of the receivership procedure to which the company is subject and having been opened by decision of the Commercial Court of Nanterre on January 24, 2023. This Court is expected to rule in the coming weeks on the follow-up to be given to this procedure and on the possible opening of judicial liquidation proceedings.
Trading of Lysogene shares will remain suspended.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.